Suzanne F. Jones

10.4k citations

231 papers · 7.8k indexed · 2 hit papers · h-index 42

Oncology top 0.5%
- Cancer Treatment and Pharmacology 55
- Colorectal Cancer Treatments and Studies 41
- Lung Cancer Research Studies 24
- HER2/EGFR in Cancer Research 22
Cancer Research top 1%
Genetics top 1%
Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations 54
- Advanced Breast Cancer Therapies 20
Molecular Biology top 2%
- PI3K/AKT/mTOR signaling in cancer 28
- Cancer therapeutics and mechanisms 25

Co-authors: Howard A. Burris Jeffrey R. Infante Johanna C. Bendell David R. Spigel F. Anthony Greco Stefan Rose‐John Rachel M. McLoughlin Thomas S. Wilkinson
Cited by: Oncology Cancer Research Genetics
Partner nations: United States United Kingdom Canada

In The Last Decade

Suzanne F. Jones

228 papers receiving 7.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2005 Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
2001 IL-6 and Its Soluble Receptor Orchestrate a Temporal Switch in the Pattern of Leukocyte Recruitment Seen during Acute Inflammation

Peers

Countries citing papers authored by Suzanne F. Jones

Since Specialization

Citations

This map shows the geographic impact of Suzanne F. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne F. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne F. Jones more than expected).

Fields of papers citing papers by Suzanne F. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne F. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne F. Jones. The network helps show where Suzanne F. Jones may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Suzanne F. Jones, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Suzanne F. Jones Line = papers co-authored together Suzanne F. Jones links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial Erika Hamilton,Gerald S. Falchook,Judy S. Wang,Siqing Fu,Amit M. Oza,Esteban Rodrigo Imedio,Sanjeev Kumar,Lone H. Ottesen,Ganesh Mugundu,Elza C. de Bruin,Mark J. O’Connor,Suzanne F. Jones,David R. Spigel,Bob T. Li	2024	3
2	A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors Gerald S. Falchook,Jasgit C. Sachdev,Esteban Rodrigo Imedio,Sanjeev Kumar,Ganesh Mugundu,Suzanne Jenkins,Juliann Chmielecki,Suzanne F. Jones,David R. Spigel,Melissa L. Johnson	2023	17
3	A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors Todd M. Bauer,Kathleen N. Moore,Janet S. Rader,Fiona Simpkins,Alain C. Mita,J. Thaddeus Beck,Lowell L. Hart,Quincy S. Chu,Amit M. Oza,Anna V. Tinker,Esteban Rodrigo Imedio,Sanjeev Kumar,Ganesh Mugundu,Suzanne Jenkins,Juliann Chmielecki,Suzanne F. Jones,David R. Spigel,Siqing Fu	2023	21
4	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor David S. Hong,Kathleen N. Moore,Johanna C. Bendell,Daniel D. Karp,Judy S. Wang,Susanna V. Ulahannan,Suzanne F. Jones,Wenjuan Wu,Gregory P. Donoho,Yan Ding,Andrew Capen,Xuejing Wang,Aimee Bence Lin,Manish R. Patel	2021	37
5	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group Alexander I. Spira,Mark Stewart,Suzanne F. Jones,Elaine Chang,Anitra Fielding,Nicole Richie,Laura S. Wood,Michael A. Thompson,Lee Jones,Abhilasha Nair,Brandon A. Mahal,David E. Gerber	2021	20
6	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma David S. Hong,Kathleen N. Moore,Manish R. Patel,Stefan C. Grant,Howard A. Burris,William N. William,Suzanne F. Jones,Funda Meric‐Bernstam,Jeffrey R. Infante,Lisa Golden,Wei Zhang,Ricardo Martínez,Sameera R. Wijayawardana,Richard P. Beckmann,Aimee Bence Lin,Cathy Eng,Johanna C. Bendell	2018	62
7	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer David S. Hong,Jeffrey R. Infante,Filip Jankú,Suzanne F. Jones,Ly M. Nguyen,Howard A. Burris,Aung Naing,Todd M. Bauer,Sarina A. Piha‐Paul,Faye M. Johnson,Razelle Kurzrock,Lisa Golden,Scott M. Hynes,Ji Lin,Aimee Bence Lin,Johanna C. Bendell	2016	118
8	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors Suzanne F. Jones,Lillian L. Siu,Johanna C. Bendell,James M. Cleary,Albiruni R. Abdul Razak,Jeffrey R. Infante,Shuchi S. Pandya,Philippe L. Bédard,Kristen J. Pierce,Brett E. Houk,W. Gregory Roberts,S. Martin Shreeve,Geoffrey I. Shapiro	2015	125
9	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors Anthony W. Tolcher,Johanna C. Bendell,Kyriakos P. Papadopoulos,Howard A. Burris,Amita Patnaik,Suzanne F. Jones,Drew Rasco,Donna S. Cox,M. Durante,Kevin M. Bellew,J. Park,N.T. Le,Jeffrey R. Infante	2014	100
10	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer Johanna C. Bendell,Michael S. Gordon,Herbert I. Hurwitz,Suzanne F. Jones,David S. Mendelson,Gerard C. Blobe,Neeraj Agarwal,Carolyn H. Condon,Dawn Wilson,Amelia E. Pearsall,Yijun Yang,Ty McClure,Kenneth M. Attie,Matthew L. Sherman,Sunil Sharma	2013	47
11	A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours Jeffrey R. Infante,Kyriakos P. Papadopoulos,Johanna C. Bendell,Amita Patnaik,Howard A. Burris,Drew Rasco,Suzanne F. Jones,Lon Smith,Donna S. Cox,M. Durante,Kevin M. Bellew,Joo‐Hyun Park,Ngocdiep T. Le,Anthony W. Tolcher	2013	64
12	Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib Grace K. Dy,Jeffrey R. Infante,Sabine Eckhardt,Silvia Novello,Wen Wee,Suzanne F. Jones,Anne Huff,Qiong Wang,A. Benjamin Suttle,Lone H. Ottesen,Alex A. Adjei,Howard A. Burris	2012	4
13	Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies Glen J. Weiss,Jeffrey R. Infante,E. Gabriela Chiorean,Mitesh J. Borad,Johanna C. Bendell,Julian R. Molina,Raoul Tibes,Ramesh K. Ramanathan,Karen Lewandowski,Suzanne F. Jones,Mario E. Lacouture,Virginia K. Langmuir,Hank Lee,Stew Kroll,Howard A. Burris	2011	122
14	Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer Ian E. Krop,Muralidhar Beeram,Shanu Modi,Suzanne F. Jones,Scott N. Holden,Wei Yu,Sandhya Girish,Jay Tibbitts,Joo‐Hee Yi,Mark X. Sliwkowski,Fred Jacobson,Stuart Lutzker,Howard A. Burris	2010	437
15	A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer David R. Spigel,John D. Hainsworth,Jitendra G. Gandhi,Victor G. Gian,James D. Peyton,Kimberly West-Osterfield,Bobby L. Clark,Elizabeth R. Vázquez,Suzanne F. Jones,Howard A. Burris,F. Anthony Greco	2010	4
16	A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors Roger B. Cohen,Suzanne F. Jones,Charu Aggarwal,Margaret von Mehren,Jonathan Cheng,David R. Spigel,F. Anthony Greco,Mariangela Mariani,Maurizio Rocchetti,Roberta Ceruti,Silvia Comis,B. Laffranchi,Jürgen Moll,Howard A. Burris	2009	78
17	Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer Anna Maria Storniolo,Mark D. Pegram,Beth Overmoyer,Paula Silverman,N. W. Peacock,Suzanne F. Jones,Jill Loftiss,Nikita Arya,Kevin M. Koch,Elaine Paul,Lini Pandite,Ronald A. Fleming,Peter F. Lebowitz,Peter Ho,Howard A. Burris	2008	89
18	A Randomized Phase II Trial of Oral Topotecan Versus Docetaxel in the Second-Line Treatment of Non–Small-Cell Lung Cancer Suzanne F. Jones,Dana S. Thompson,John H. Barton,Jeff Patton,Dianna Shipley,F. Anthony Greco,David R. Spigel,J. Infante,Howard A. Burris	2008	11
19	A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. Branimir I. Šikić,Heather A. Wakelee,Margaret von Mehren,Nancy Lewis,E. Ruth Plummer,A H Calvert,Norma Lynn Fox,Elizabeth Kumm,Suzanne F. Jones,Howard A. Burris	2007	33
20	Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomasbreakdown → Howard A. Burris,Herbert I. Hurwitz,Elizabeth Claire Dees,Afshin Dowlati,Kimberly Blackwell,Bert H. O’Neil,P. Kelly Marcom,Matthew J. Ellis,Beth Overmoyer,Suzanne F. Jones,Jennifer L. Harris,Deborah A. Smith,Kevin M. Koch,Andrew G. Stead,Steve Mangum,Neil L. Spector	2005	503

About Suzanne F. Jones

Suzanne F. Jones is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 231 papers that have together received 7.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (55 papers), Lung Cancer Treatments and Mutations (54 papers), Colorectal Cancer Treatments and Studies (41 papers), PI3K/AKT/mTOR signaling in cancer (28 papers), Cancer therapeutics and mechanisms (25 papers), Lung Cancer Research Studies (24 papers), HER2/EGFR in Cancer Research (22 papers) and Advanced Breast Cancer Therapies (20 papers). The work is most often cited by research in Oncology (4.1k citations), Cancer Research (1.1k citations) and Genetics (699 citations). Suzanne F. Jones has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Howard A. Burris, Jeffrey R. Infante, Johanna C. Bendell, David R. Spigel, F. Anthony Greco, Stefan Rose‐John, Rachel M. McLoughlin, Thomas S. Wilkinson, Nicholas Topley and Sankichi Horiuchi.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact